| 7.19 0.13 (1.84%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.4 | 1-year : | 10.2 |
| Resists | First : | 8.05 | Second : | 8.73 |
| Pivot price | 7.39  |
|||
| Supports | First : | 6.94 | Second : | 5.78 |
| MAs | MA(5) : | 7.21 |
MA(20) : | 7.51 |
| MA(100) : | 8.21 |
MA(250) : | 9.47 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 11.8 |
D(3) : | 13.2 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 13.5 | Low : | 5.98 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AURA ] has closed above bottom band by 29.8%. Bollinger Bands are 29.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.2 - 7.22 | 7.22 - 7.26 |
| Low: | 6.95 - 6.98 | 6.98 - 7.02 |
| Close: | 7.13 - 7.18 | 7.18 - 7.24 |
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Fri, 19 Apr 2024
(AURA) Proactive Strategies - Stock Traders Daily
Mon, 15 Apr 2024
Raj Parekh to Exit Board at Aura Biosciences' Meeting - TipRanks.com - TipRanks
Tue, 02 Apr 2024
The Globe and Mail - The Globe and Mail
Wed, 27 Mar 2024
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 - InvestorPlace
Wed, 27 Mar 2024
Is it Time to Dump Aura Biosciences Inc (AURA) Stock After it Has Fallen 6.58% in a Week? - InvestorsObserver
Wed, 07 Feb 2024
(AURA) Investment Analysis - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 83.1 (%) |
| Shares Short | 2,450 (K) |
| Shares Short P.Month | 2,140 (K) |
| EPS | -1.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.2 % |
| Return on Equity (ttm) | -36.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | -39 (M) |
| PE Ratio | -3.73 |
| PEG Ratio | 0 |
| Price to Book value | 1.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|